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Collagen IV is a major component of the vascular basement membrane and may be a marker of angiogenesis. Serum levels of this
protein are elevated in some human cancers. Our objectives were to compare collagen IV levels in the serum of breast cancer
patients and healthy women and to examine changes during preoperative chemotherapy. Sera from 51 patients with stage II–III
breast cancer and 55 healthy controls were analysed. Collagen IV level was measured by a commercially available sandwich enzyme
link immunoassay. Baseline serum levels were compared between cancer patients and healthy women and paired pre- and post-
chemotherapy measurements were also performed in 39 patients who received preoperative chemotherapy and were correlated
with response to therapy. The median serum collagen IV concentration was significantly higher in cancer patients (166mgl
 1) than in
healthy women (115mgl
 1), Po0.001. Chemotherapy induced a significant further increase in serum collagen IV (167mgl
 1
prechemo vs 206mgl
 1 postchemo, P¼0.001). There were no correlations between baseline collagen IV levels and response to
therapy, age, clinical stage or HER2 status. In conclusion, patients with breast cancer have elevated levels of collagen IV compared to
healthy women and collagen IV levels increase further during chemotherapy.
British Journal of Cancer (2008) 99, 68–71. doi:10.1038/sj.bjc.6604443 www.bjcancer.com
Published online 17 June 2008
& 2008 Cancer Research UK
Keywords: serum collagen IV; breast cancer; primary chemotherapy; collagen IV; HER-2
                                                 
Collagen IV is a major component of the basement membrane that
surrounds tumour vasculature (Yurchenko and O’Rear, 1993;
Aumailley and Gayraud, 1998; Baluk et al, 2003). Collagen IV is
synthesized during angiogenesis and is deposited around the
endothelial cells and pericytes and could be considered as a marker
of angiogenic activity (Baluk et al, 2003). Elevated collagen IV
levels were also documented in patients with liver cirrhosis and
chronic renal diseases compared to healthy individuals (Hong
et al, 1995; Xu et al, 2002). Degradation of this protein occurs
during invasion and metastatic spread of cancer (Robledo et al,
2005). High collagen IV levels were detected in the serum of
patients with metastatic breast, colorectal, gastric and lung cancers
as well as primary liver cancer (Ambiru et al, 1995; Hong et al,
1995). One abstract reported that baseline levels of this protein and
changes during treatment may be markers of response to
antiangiogenic therapy in cancer (Ayers et al, 2007). Collagen IV
mRNA is highly expressed in breast cancer stroma and immuno-
histochemistry studies indicated that this protein was a major
component of breast tumour vasculature (Lipponen et al, 1994;
Symmans et al, 2003). However, serum collagen IV levels were not
previously measured in breast cancer. We hypothesized that serum
collagen IV levels maybe elevated in patients with primary breast
cancer relative to healthy women because of increased angiogenic
activity in the cancer. The goal of this study was to test this
hypothesis and also to assess changes in collagen IV levels in a
subset of patients during preoperative chemotherapy.
METHODS
Patients and samples
Archived serum specimens were used for this research. Sera were
obtained at baseline (before therapy) and after completion of 6
months of preoperative chemotherapy but before surgery from 39
HER-2-positive breast cancer patients who participated in a
preoperative clinical trial. Patients were randomised to receive
either four cycles of paclitaxel followed by four cycles of
fluorouracil, cyclophosphamide and epirubicin or the same
chemotherapy in combination with trastuzumab. Results of this
clinical trial were reported previously (Buzdar et al, 2005).
Aliquots of the same serum samples were previously used to
measure changes in serum troponin levels and in circulating HER-
2 receptor domain during preoperative therapy (Buzdar et al, 2005;
Mazouni et al, 2007). We requested additional serum specimens
from an investigator-initiated serum bank (Dr B Arun) that
included sera from 12 more cancer patients with HER2-normal
(n¼8), HER-2-positive (n¼1) or HER-2 unknown disease (n¼3)
and from 55 healthy women volunteers whose serum was accrued
during the same time period as those of the cancer patients.
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sVolunteers with history of liver disease or other chronic
inflammatory condition were excluded. All cancer patients were
free of liver metastasis or any acute or chronic liver or kidney
disease. The volunteers were slightly younger than the cancer
patients; the median ages were 46 years (range, 21–70 years) and
52 years (range, 22–68 years) respectively, (P¼0.04). Table 1
summarises clinical characteristics of the cancer patients. Only two
patients had a recurrence in the entire cancer cohort due to short
median follow up.
The total number of cases included in this study is 107 (51
cancer and 55 healthy women). The total number of specimens is
146 including 107 baseline measurements and 39 repeat measure-
ments before and after completion of 6 months of chemotherapy in
a subset of the cancer patients who participated in the preoperative
clinical trial. All samples were centrifuged and aliquoted after
collection and stored at  801C until the assays were performed. No
repeat freezing or thawing was permitted. All patients and
volunteers signed informed consent before collection of serum
or tumour specimens at the UT MD Anderson Cancer Center and
the local Medical Ethics Committee (IRB) approved this laboratory
study on stored specimens.
Collagen IV immunoassay
Serum collagen IV was measured with a commercially available
enzyme immunoassay using monoclonal antibodies against the
central triple helical region of human type IV Collagen (Collagen
IV ELISA, Biotrin, Daiichi Fine Chemical Co. Ltd., Ireland). The
measurements were performed following the instructions of the
manufacturer. The coefficients of variation for both inter- and
intra-assay variability of the assay were previously reported and
were p4.0% (Obata et al, 1989). A standard dilution of collagen IV
supplied with the assay was used to calibrate the measurements.
Six formaldehyde-fixed paraffin-embedded primary tumour
specimens that matched baseline serum samples could also be
retrieved from the institutional tumour bank. Immunohisto-
chemical staining was performed after antigen heat retrieval in
citrate buffer (pH¼6) in a steamer for 10min. Primary antibodies
were used against CD34 (BD Bioscience, 1:20 dilution) and VEGF
(Santa Cruz, 1:10). A standard three-step avidin–biotin per-
oxidase complex technique was used for visualisation of the
antigens using DAB as the chromogen. A distinct brown staining
in the cytoplasm of the cells was regarded as positive staining.
Statistical analysis
w
2 or Fisher exact tests were used to compare differences between
categorical variables. Differences in continuous variables were
analysed using the Mann–Whitney U-tests. The Wilcoxson test
was used to compare collagen IV concentration before and after
treatment. A P-value o0.05 was considered significant. The
correlation between age and serum collagen IV levels was assessed
using the Spearman’s correlation coefficient. Statistical analyses
were performed with SPSS
s software version 12.0.
RESULTS
Baseline serum collagen IV levels differ between breast
cancer patients and healthy women
The median serum collagen IV concentration was 166ngml
 1
(range, 85–327ngml
 1) in breast cancer patients (n¼51) and it
was 115ngml
 1 (range, 61–339ngml
 1) in healthy volunteers
(n¼55) (Figure 1). Mean serum levels were also different 174 vs
118ngml
 1, respectively and these differences were statistically
significant (Po0.001). However, individual measurements over-
lapped substantially between the two groups. Next, we correlated
collagen IV levels with clinical stage. The median concentration
was 178ngml
 1 in stage I cancers (n¼10), it was 156ngml
 1 in
stage II (n¼29), and 167ngml
 1 in stage III (n¼10) tumours.
Clinical stage could not be determined for two cases (P¼0.21).
Table 1 Patient characteristics
Characteristics Patients n¼51 (100%)
Median age at diagnosis 52 (range, 21–70)
o50 years 20 (39%)
X50 years 31 (61%)
Tumour size
T1 10 (19.6)
T2 29 (56.9)
T3 9 (17.6)
T4 1 (2)
NA 2 (3.9)
Clinical nodal status at diagnosis
Positive 26 (51)
Negative 23 (45.1)
Unknown 2 (3.9)
Oestrogen receptor status
Positive 28 (54.9)
Negative 21 (41.2)
Unknown 2 (3.9)
Progesterone receptor status
Positive 20 (39.2)
Negative 29 (56.9)
Unknown 2 (3.9)
HER-2 status
Positive 40
Negative 8
Unknown 3
Type of preoperative chemotherapy
H+T/FAC 29
T/FEC 13
None 9
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Figure 1 Comparison of median concentration of collagen IV between
breast cancer patients (n¼51) and healthy volunteers (n¼55).
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sThese differences were not significantly different, P¼0.21. These
results indicate that collagen IV concentrations are generally
higher in the serum of women with breast cancer compared to
healthy individuals, but individual variations are substantial and
are not related to clinical stage.
We also examined the influence of age on collagen IV levels,
mean (139.1 vs 151.2ngml
 1, P¼0.25) and median (122.6 vs
137.8ngml
 1, P¼0.06) collagen IV levels were not significantly
different between women younger than 50 years of age (n¼56) or
older (n¼50) years of age with or without cancer. There was no
relationship between age and collagen IV levels (r¼ 0.102,
P¼0.48). We performed an exploratory analysis and compared
collagen IV levels between HER2-positive (n¼40) and HER-2
normal cancers (n¼8) at baseline, there was no significant
difference in the mean (166.3 vs 176ngml
 1, P¼0.61) or median
(156.9 vs 169.2ngml
 1, P¼0.29) collagen IV levels between these
2 groups.
Unfortunately, we could not retrieve most of the primary
tumour biopsies from the patients who were included in the serum
study to correlate angiogenic activity within the primary tumour
and serum collagen IV levels. Immunohistochemistry results for
collagen IV (CD34) and VEGF were available on six cases. There
was no clear correlation between IHC staining for these markers
and collagen IV levels.
Changes in collagen IV levels after preoperative
chemotherapy
The mean serum collagen IV concentration prior to chemotherapy
was 167ngml
 1 (range, 85–327) in the 39 patients who subse-
quently received 6 months of preoperative chemotherapy with or
without trastuzumab. The mean serum collagen concentration
had risen to 206ngml
 1 (range, 119–480) after completion of
chemotherapy but before definitive surgery (Figure 2). This
increase was statistically significant, Po0.001. However, there
was no difference in the mean baseline serum collagen IV
concentration (172ngml
 1) of those who achieved pathologic
complete response (pCR¼no invasive cancer in the breast or
lymph nodes after chemotherapy) and those with lesser response
(any residual invasive cancer at surgery), 161ngml
 1; P¼0.90.
Similarly, there was no difference in mean collagen IV concentra-
tions after chemotherapy in the two different response groups
(206ngml
 1 each). Post-chemotherapy collagen IV levels were
also similar regardless of the type of treatment that was
given, chemotherapy alone (181ngml
 1) vs chemotherapy plus
trastuzumab (191ngml), P¼0.37.
DISCUSSION
To our knowledge, this is the first study that examined serum
collagen IV levels in early stage breast cancer patients and in
healthy women. We found that patients with stage II–III breast
cancer have significantly higher levels of collagen IV in their blood
than healthy women. These results are concordant with previous
studies in others type of cancers. Hong et al (1995) reported higher
concentrations of serum collagen IV in liver carcinoma and in
patients with metastatic colon cancer compared to healthy
subjects. Also, in colorectal cancer, higher collagen IV levels were
detected in patients with liver metastasis compared to those
without metastasis (Ambiru et al, 1995). Increased levels of this
protein in the blood of cancer patients may be an indicator of high
level of angiogenesis or may be because of increased degradation
due to the invasion process (Hewitt et al, 1992). High degree of
individual variation including up to fivefold differences in serum
collagen IV concentration among cancer patients suggests that this
molecule may be worth studying as a potential marker of
angiogenic activity.
Our study has several limitations; the sample size is small
and does not allow sufficiently powered subset analysis. The
median age of the cancer patients was significantly older than the
median age of the volunteers. This may introduce a bias and the
differences that we report between cancer cases and controls
may be due to age. However, we also compared collagen IV levels
between younger and older cancer patients and did not detect a
significant difference by age. We were not able to examine the
impact of timing of the diagnostic core needle biopsy and
serum collagen levels. One may hypothesize that the small invasive
procedure could on its own lead to increased collagen IV levels
due to tissue injury. However, the time between the diagnostic
biopsy and collection of serum always exceeded 1 week which
makes this hypothesis somewhat less likely. The samples
were stored uniformly and spanned a similar collection and
storage period; therefore sample handling or differences in storage
length are unlikely to contribute to the observed difference in
collagen IV levels. We attempted to correlate serum levels
with collagen IV expression and angiogenesis in the primary
tumour at the time of diagnosis but could only retrieve six of the
51 tumour specimens. This analysis therefore was underpowered
to detect any but the most dramatic association. To conclude, we
observed a difference in serum collagen IV levels between healthy
women and breast cancer patients; however, the small sample size
and lack of inclusion of benign breast disease (e.g. in situ cancers,
adenomas, atypical proliferative lesions) preclude us to define the
sensitivity or specificity and positive or negative predictive
values of this serum marker. Thus our cohort is too small to
establish the use of collagen IV as a biomarker and it is not
possible to determine the sensitivity or specificity of collagen IV
from this study.
In this study, collagen IV levels increased significantly during
preoperative chemotherapy. Similar increase in serum collagen IV
was also reported in colon cancer that persisted for several months
after treatment (Kudo et al, 2002). Why collagen IV levels
increased in response to cytotoxic therapy is unclear. It may be
due to vascular membrane destruction by chemotherapy or
increase in angiogenic activity in response to cellular stress in
the cancer induced by chemotherapy. It is intriguing that the post-
chemotherapy increase appeared steeper in patients with residual
disease (P¼0.002) compared to those who achieved complete
eradication of the cancer (pCR). This suggests that tumour-related
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Figure 2 Median serum collagen IV concentrations at baseline and after
completion of 6 months of preoperative chemotherapy (n¼39).
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sfactors may regulate the release of collagen IV into the circulation.
We did not measure other potential markers of angiogenesis or
tissue remodeling during this study. Collagen IV may serve as a
potential marker of tumour angiogenesis and further studies may
be warranted to examine if patients with higher serum collagen IV
concentrations are more susceptible to angiogenesis inhibitors and
if changes in collagen IV levels could be used to monitor treatment
effect.
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